Table 2.
Expression of cancer stem cell markers according to the American Thyroid Association 2009 Risk Stratification System.
| Total N = 386 (%) | ATA low risk group n = 42 (%) | ATA intermediate risk group n = 344 (%) | p-value | |
|---|---|---|---|---|
| CD15 | 0.017 | |||
| Negative | 280 (72.5) | 37 (88.1) | 243 (70.6) | |
| Positive | 106 (27.5) | 5 (11.9) | 101 (29.4) | |
| CD24 | 0.999 | |||
| Negative | 384 (99.5) | 42 (100.0) | 342 (94.4) | |
| Positive | 2 (0.5) | 0 (0.0) | 2 (0.6) | |
| CD44 | 0.052 | |||
| Negative | 76 (19.7) | 13 (31.0) | 63 (18.3) | |
| Positive | 310 (80.3) | 29 (69.0) | 281 (81.7) | |
| CD166 | 0.347 | |||
| Negative | 339 (87.8) | 35 (83.3) | 304 (88.4) | |
| Positive | 47 (12.2) | 7 (16.7) | 40 (11.6) | |
| ALDH1A1 | 0.212 | |||
| Negative | 378 (97.9) | 40 (95.2) | 338 (98.3) | |
| Positive | 8 (2.1) | 2 (4.8) | 6 (1.7) |
ATA, American thyroid association. Bold value indicates statistically significant (p <0.05).